ClinConnect ClinConnect Logo
Search / Trial NCT05720338

Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?

Launched by CASE COMPREHENSIVE CANCER CENTER · Feb 6, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Pancreatic Neoplasm

ClinConnect Summary

This clinical trial is studying whether it is necessary to use a drainage tube in the abdomen after a specific type of surgery called distal pancreatectomy, which involves removing part of the pancreas. Researchers want to find out if patients who do not have the drainage tube experience the same rate of complications, such as infections or problems with healing, as those who do have the tube. The trial is looking for patients aged 18 and older who are scheduled for this surgery and are able to understand and sign a consent form.

If you participate in this trial, you will be randomly assigned to either have the drainage tube placed or not after your surgery. The study aims to ensure that both groups have similar outcomes, so you will be helping researchers understand the best approach for patients undergoing this type of surgery. It's important to note that some patients may not be eligible, such as those under 18, pregnant women, or individuals who have had certain previous surgeries. If you're interested in participating, be sure to discuss it with your healthcare team.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Subjects must be undergoing a scheduled distal pancreatectomy (with or without concurrent splenectomy)
  • Age ≥18 years
  • Subjects must have the ability to understand and the willingness to sign a written informed consent document.
  • Exclusion Criteria:
  • Patients \< 18 years old
  • Patients who are pregnant
  • Patients with a history of previous pancreatic surgery
  • Patients with a history of prior gastric resection, gastric bypass or sleeve gastrectomy
  • Patients with prior cystogastrostomy procedure
  • Patients who have failed prior endoscopic intervention or ultrasound due to esophageal or other gastrointestinal stricture
  • Patients with Type 3 or Type 4 Paraesophageal Hernia noted either on pre-operative imaging or intra-operatively
  • Patients undergoing concurrent resection of organs other than the pancreas or spleen or gallbladder
  • Patients who undergo oversewing of the pancreatic transection margin
  • Patients with unexpected intraoperative bleeding or adhesive disease which deem it unsafe to proceed without an intraabdominal drain
  • Patients who are unable to provide informed consent

About Case Comprehensive Cancer Center

Case Comprehensive Cancer Center is a leading academic research institution dedicated to advancing cancer care through innovative clinical trials and cutting-edge research. As a National Cancer Institute-designated Comprehensive Cancer Center, it integrates multidisciplinary approaches to cancer prevention, diagnosis, and treatment, fostering collaboration among clinicians, researchers, and patients. The center is committed to translating scientific discoveries into effective therapies, enhancing patient outcomes, and contributing to the global body of cancer knowledge. With a robust portfolio of clinical trials, Case Comprehensive Cancer Center aims to address the unmet needs of cancer patients and drive progress in the fight against cancer.

Locations

Cleveland, Ohio, United States

Patients applied

0 patients applied

Trial Officials

Robert Simon, MD

Principal Investigator

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials